David Poon
Director/Board Member chez LifeSciences British Columbia
Profil
David K.
Y.
Poon is currently the Director at LifeSciences British Columbia and the Chief Business Officer at Gandeeva Therapeutics, Inc. He previously worked as the Manager-Business Development at Zymeworks BC, Inc. from 2007 to 2019.
He holds a doctorate degree from the University of British Columbia.
Postes actifs de David Poon
| Sociétés | Poste | Début |
|---|---|---|
LifeSciences British Columbia
 LifeSciences British Columbia BiotechnologyHealth Technology LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada. | Director/Board Member | 12/09/2023 |
Gandeeva Therapeutics, Inc.
 Gandeeva Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Gandeeva Therapeutics, Inc. is a Canadian company that specializes in drug discovery using a unique approach to develop precision medicines. The company is based in Vancouver, Canada and was founded by Sriram Subramaniam, who has been the CEO since incorporation. The company's focus is on understanding the language by which proteins communicate in vivo, which is fundamental to deciphering biology. The company's discovery process involves identifying the optimal protein-protein interactions and altering protein structures to develop drugs that can treat various diseases. | Corporate Officer/Principal | - |
Anciens postes connus de David Poon
| Sociétés | Poste | Fin |
|---|---|---|
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | - |
Formation de David Poon
| University of British Columbia | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
LifeSciences British Columbia
LifeSciences British Columbia BiotechnologyHealth Technology LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada. | Health Technology |
Gandeeva Therapeutics, Inc.
Gandeeva Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Gandeeva Therapeutics, Inc. is a Canadian company that specializes in drug discovery using a unique approach to develop precision medicines. The company is based in Vancouver, Canada and was founded by Sriram Subramaniam, who has been the CEO since incorporation. The company's focus is on understanding the language by which proteins communicate in vivo, which is fundamental to deciphering biology. The company's discovery process involves identifying the optimal protein-protein interactions and altering protein structures to develop drugs that can treat various diseases. | Commercial Services |
